The views expressed in this content represent the perspective and opinions of the author and may or may not represent the position of Indiana University School of Medicine.
IU School of Medicine
With more than 60 academic departments and specialty divisions across nine campuses and strong clinical partnerships with Indiana’s most advanced hospitals and physician networks, Indiana University School of Medicine is continuously advancing its miss...
Indiana University School of Medicine is leading the first study of the national Diabetic Foot Consortium with the goal of preventing reopening of closed wounds by identifying a biomarker that would predict such recurrence during the process of standard wound care.
Indiana University School of Medicine announced today a strategic research agreement with Eli Lilly and Company designed to ultimately benefit people suffering from a variety of autoimmune diseases. The five-year, five-million-dollar deal will span multiple projects and teams. The purpose of the agreement is to gain an understanding of the molecular and cellular changes which occur in patients after administration of some of Lilly’s currently marketed autoimmune therapies that are also being developed for the potential of new autoimmune diseases, including inflammatory bowel disease and psoriasis.
Indiana University School of Medicine has picked an internationally recognized geneticist with more than two decades of experience with the institution to lead its $360 million research enterprise. Tatiana Foroud, PhD has been named the new Executive Associate Dean for Research Affairs and IU Health’s Executive Vice President of Academic Affairs for Clinical Research, effective August 1, 2020.
Indiana University School of Medicine researchers Milan Radovich, PhD, and Bryan Schneider, MD, have discovered that the presence of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in the plasma of women’s blood who have undergone chemotherapy prior to surgery for the treatment of stage 1, 2 or 3 triple negative breast cancer are critical indicators for the prediction of disease recurrence and disease-free survival.
Led by Nancy Swigonski, MD and Mary Ciccarelli, MD, a team of faculty at Indiana University School of Medicine have developed a statewide early autism spectrum disorder screening and evaluation system in the primary care setting showing success in improving access to evaluations and lowering the age of diagnosis. This study, published July 6 in Pediatrics, is the first of its kind in the U.S. to include health care systems across an entire state.
A new grant is helping Indiana University School of Medicine Department of Psychiatry strengthen its position as a national leader in addiction psychiatry training and patient care through expansion of the addiction psychiatry program and nationwide implementation of a model of care developed at IU School of Medicine.
A team of international researchers has learned that dose escalation of hydroxyurea treatment for children in Uganda with sickle cell anemia is more effective and has similar side effects than a lower fixed dose of the same drug. The study, known as NOHARM MTD (Novel use Of Hydroxyurea in an African Region with Malaria – Maximum Tolerated Dose), focused on children in Uganda, but the results could impact use of hydroxyurea worldwide, including the United States and Europe. The findings are being published in the June 25 issue of the New England Journal of Medicine.
INDIANAPOLIS — The Indiana Clinical and Translational Sciences Institute (CTSI) announced today that Sharon M. Moe, MD and Sarah E. Wiehe, MD, MPH have assumed the roles of co-leaders of the institute that is focused on improving health in Indiana through a research partnership among the state’s leading research universities of Indiana University (IU), Purdue University and the University of Notre Dame.